Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

522 trials

NCT06910657
Recruiting
IDOV-Immune for Advanced Solid Tumors
Phase 1 · Australia, United States · 5 sites
Registry update: 5 Aug 2026
NCT07020117
Recruiting
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 · United States · 14 sites
Registry update: 17 Sept 2026
NCT07090499
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase 1 · Canada, China, Spain, United Kingdom, Puerto Rico, United States · 30 sites
Registry update: 5 Nov 2026
NCT07067749
Recruiting
Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
Phase 3 · Italy · 1 site
Registry update: 24 Jul 2025
NCT07050771
Recruiting
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
Phase 2 · United States · 1 site
Registry update: 12 Mar 2026
NCT06774131
Recruiting
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Phase 3 · Bulgaria, Spain, Georgia, Hungary, Israel, Latvia, Poland, Romania, United States · 79 sites
Registry update: 3 Sept 2026
NCT07119996
Recruiting
Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients
Phase 1 · China · 1 site
Registry update: 30 Jun 2026
NCT07087860
Recruiting
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Phase 2 · United States · 1 site
Registry update: 8 May 2026
NCT07314723
Recruiting
9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Phase 2 · China · 1 site
Registry update: 2 Jan 2026
NCT06537154
Recruiting
NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment
Phase 2/3 · Canada · 1 site
Registry update: 30 Jul 2025
NCT06967961
Recruiting
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
Not applicable · France · 1 site
Registry update: 15 Jun 2026
NCT06356155
Recruiting
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer
Phase 2 · United States · 2 sites
Registry update: 16 Jul 2026
NCT07088536
Recruiting
Occupational Situation and Return to Work of Urological Patients
Not applicable · Poland · 1 site
Registry update: 3 Mar 2026
NCT07318051
Recruiting
Sample Collection for Ongoing Research and Product Evaluation Study
Not applicable · United States · 1 site
Registry update: 15 Jan 2026
NCT07000084
Recruiting
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Phase 3 · United States · 60 sites
Registry update: 2 Oct 2026
NCT07506057
Recruiting
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy
Phase 2 · China · 1 site
Registry update: 1 Apr 2026
2024-516870-31-00
Recruiting
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors
Phase 1 · Netherlands · 2 sites
Registry update: 28 May 2026
NCT07043972
Recruiting
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
Phase 2 · United States · 2 sites
Registry update: 17 Sept 2026
NCT07126119
Recruiting
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC
Phase 2 · China · 1 site
Registry update: 17 Aug 2025
NCT07048496
Recruiting
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
Not applicable · United States · 1 site
Registry update: 5 Oct 2026

Ordered by registry start date. Freshness and sponsorship never change the order.